Banner and CPC Partner To Launch the ARTHx Brand In Consumer-Preferred Soflet ® Dosage Form

HIGH POINT, NC — Banner Pharmacaps Inc., a leading global innovator of drug delivery technology and proprietary health care products, announces its collaboration with Contract Pharmacal Corporation (CPC) to begin the launch of CPC’s recent acquisition of the ARTHx brand of Joint Support products using Banner’s patented Soflet ® Gelcap technology.

The Soflet ® Gelcap dosage form is increasingly preferred by consumers because of the ease of swallowing as well as taste and odor masking properties imparted by the gelatin coating. Research also shows that consumers prefer the appearance of gelcap products to tablets.

Banner’s proprietary, patented Soflet ® Gelcap technology is unique in the industry. Banner takes tablets one step further by applying an innovative, tamper evident/tamper resistant process that adheres to the core, preventing the gelatin from being removed by mechanical device without removing part of the core.

“We chose to partner with Banner Pharmacaps because of its patented technology, excellent reputation, and customer service,” said Mathew Wolf, vice president of sales for CPC. “The majority of ARTHx customers are older adults who are looking for a fast-acting, premium quality drug delivery form that is easy to swallow, tasteless and odor-free. Banner’s Soflet ® Gelcap technology will help maintain and build consumer preference for our ARTHx brand in the joint support product category.”

Because of the strong consumer preference and brand-building possibilities associated with this proprietary dosage form, Soflet ® Gelcap technology will be available in ARTHx Fast-Acting Glucosamine and Chondrotin with Hyaluronic Acid, and will be available in ARTHx Double Strength and ARTHx Triple Strength.

“This partnership is one that has a lot of potential for future applications joining Banner’s technologies with CPC’s products,” said John Barbee, senior vice president of nutritional sales and marketing at Banner. “Banner’s patented technologies can extend product lines or launch new brands, and we are pleased to be joining forces with CPC to make that happen.”

Banner holds a family of worldwide Soflet ®Gelcap patents that protect the Soflet ® processes and machinery. “Offering our customers these patented and proprietary products strengthens our position as a leader in global drug delivery technologies and innovations,” said Dr. Roger Gordon, president of Banner.

Banner is a global company that researches, develops, and manufactures drug delivery technologies and proprietary health care products. With state-of-the-art, FDA-approved manufacturing facilities and significant investment in research and development, Banner provides innovative oral delivery solutions and unique products to the health care industry worldwide. A wholly owned subsidiary of Sobel N.V., Banner has operations in the United States, Canada, Europe, Latin America and Asia-Pacific.

Contract Pharmacal Corp. (CPC) is a FDA-inspected, prime manufacturer and packager of nutritional supplements, over-the-counter drugs, and prescription pharmaceuticals. Since 1971, CPC’s emphasis on creative production development, quality assurance, and cost efficiency has propelled it to the forefront of the pharmaceutical industry. CPC reliably provides more than one thousand quality pharmaceutical and nutritional products to hundreds of millions of customers worldwide.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.